Marker Predicts Outcomes in mCRPC Treated With AR-Targeted Therapy

For patients with HR–positive/HER2-negative breast cancer, neoadjuvant patritumab deruxtecan with or without letrozole showed antitumor activity.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Six-year data from the OlympiA trial support olaparib as a standard of care in BRCA-mutated, high-risk, HER2-negative primary breast cancer.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

For patients with hormone receptor-positive and HER2-low breast cancer, T-DXd elicited higher levels of PFS despite time to progression and disease burden.

Findings from a multi-institutional study show an increased risk of developing high-grade immune-related AEs among select older patients with early-stage breast cancer.